drugset / Trial / NCT04161482
An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability
Phase 1
Completed
39 enrolled
scPharmaceuticals, Inc.
CSSi Life Sciences · collabClinical Trial Data Services, LLC · collab
Non-randomizedSequentialOpen-labelOther
Summary
This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix.
Timeline
- Start
- 2019-12-02
- Primary completion
- 2020-06-24
- Completion
- 2020-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Furosemide | Other / unclassified | 80 mg | Subcutaneous |
Indications
No indication recorded.